Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
Open Access
- 1 April 2026
- journal article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 9 (2) , 201-213
Abstract
Background: Despite the success of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance remains an unmet need. Although human epidermal growth factor receptor 3 (HER3) and c-Met upregulation are key mechanisms of this resistance, the rationale for simultaneously targeting both to overcome this challenge remains unexplored. Methods: HER3 and c-Met expression were evaluated by immunohistochemistry in 270 clinical samples, including EGFR TKI-resistant NSCLC, lung adenocarcinoma (LUAD), gastric cancer, and colorectal cancer (CRC). The binding affinity of SDP0505 was measured by surface plasmon resonance and enzyme-linked immunosorbent assay, internalization was monitored using Incucyte, and in vitro cytotoxicity was assessed via CellTiter-Glo assay. The in vivo anti-tumor activities were investigated in cell-derived and patient-derived xenograft (PDX) models. Pharmacokinetics and repeated-dose toxicity were studied in cynomolgus monkeys. Results: Immunohistochemical analyses revealed spatial colocalization of HER3 and c-Met in EGFR TKI-resistant NSCLC specimens. Furthermore, high co-expression was observed in 58% of EGFR-mutant LUAD and 95% of CRC cases. Consequently, SDP0505 was developed with optimal antigen-binding affinity and antibody format through comprehensive screening. In HER3/c-Met dual-positive cell lines, SDP0505 demonstrated enhanced cell binding and internalization over the in-house synthesized U3-1402 analog. Superior in vivo antitumor efficacy was also observed in multiple NSCLC and CRC models, including EGFR TKI-resistant PDX models. Moreover, SDP0505 exhibited favorable pharmacokinetic and safety profiles in cynomolgus monkeys. Conclusions: SDP0505 represents a novel HER3 × c-Met ADC with superior internalization and anti-tumor activity in preclinical models, especially in EGFR TKI-resistant PDX models. These results supported the initiation of a Phase I clinical trial in China.Keywords
Funding Information
- Jiangsu Hengrui Pharmaceutical Co., Ltd
- Shanghai Shengdi Pharmaceutical Co., Ltd
This publication has 33 references indexed in Scilit:
- Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyThe Lancet Oncology, 2025
- 642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLCAnnals of Oncology, 2024
- Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR StudyJournal of Thoracic Oncology, 2024
- BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 studyThe Lancet Oncology, 2024
- Bispecific antibody drug conjugates: Making 1+1>2Acta Pharmaceutica Sinica B, 2024
- Antibody–drug conjugates come of age in oncologyNature Reviews Drug Discovery, 2023
- Dual‐targeting therapy against HER3/MET in human colorectal cancersCancer Medicine, 2023
- The therapeutic window of antibody drug conjugates: A dogma in need of revisionCancer Cell, 2022
- Coming-of-Age of Antibodies in Cancer TherapeuticsTrends in Pharmacological Sciences, 2016
- FDA approves two IBS drugsNature Reviews Drug Discovery, 2015